Combinatorial screening of a panel of FDA-approved drugs identifies several candidates with anti-Ebola activities.
Level 5 - mechanism / opinion, no new human data
In vitro bench study using pseudovirion and replicon assays with no human participants.
PubMed 31806372 · doi:10.1016/j.bbrc.2019.11.065
What was done
Authors conducted a combinatorial drug repurposing screen of FDA-approved drugs using in vitro Ebola virus (EBOV) pseudovirion and minigenome replicon systems. They performed mechanistic pathway analyses (investigating mevalonate biosynthesis and late endosomal homeostasis), tested class analogues (statins and cardiac glycosides), and evaluated drug combinations for synergistic antiviral effects.
What was found
The abstract reports no quantitative values (such as IC50, EC50, or synergy scores). Qualitatively, the screen identified anti-EBOV activity for azithromycin, clomiphene, chloroquine, digitoxin, epigallocatechin-gallate, fluvastatin, tetrandrine, and tamoxifen. Mechanistically, fluvastatin inhibited pseudovirion entry by blocking mevalonate biosynthesis, and azithromycin altered late endosomal vesicle homeostasis. Antiviral activity extended to other statins (e.g., simvastatin) and cardiac glycosides, and multiple drug combinations exhibited synergistic inhibition.
Why it matters
Repurposing approved drugs and identifying synergistic combinations provides potential mechanistic targets and lead candidates for treating Ebola virus infection.
Limits
The abstract provides no quantitative metrics or effect sizes. All evaluations were conducted entirely in vitro using pseudotype and replicon surrogate models rather than infectious wild-type virus, animal infection models, or human subjects.
Cited by
- context The macrolide antibiotic azithromycin exhibits antiviral activity against Ebola virus in animal models.